Serum Midkine as a Predictor of Cardiac Events in Patients With Chronic Heart Failure
Serum Midkine as a Predictor of Cardiac Events in Patients With Chronic Heart Failure
复制标题
DOI：
10.1016/j.cardfail.2009.12.014
复制
发表时间：
2010-04-01
影响因子：
6
通讯作者：
Kubota, Isa
中科院分区：
文献类型：
--
作者：
Kitahara, Tatsuro;Shishido, Tetsuro;Kubota, Isa
背景：中期因子是一种肝素结合生长因子，具有促进炎性细胞迁移、抗凋亡等多种功能。炎症细胞浸润和心肌细胞凋亡参与了心力衰竭的发生、发展过程。然而，中期因子和HF之间的关系尚未被研究。因此，我们研究了血清中期因子水平的临床意义，以确定预后的HF patients.Methods和结果：血清中期因子水平测定在入院时在216个连续的HF住院患者和60个对照组。患者进行了前瞻性随访，平均随访时间为653 - 375天，终点为心源性死亡和需要再住院的进行性心力衰竭。中期因子的血清浓度显着高于HF患者比对照组。发生心脏事件的患者的中期因子浓度显著高于未发生心脏事件的患者。Kaplan-Meier分析显示心脏事件发生率随着中期因子水平的升高而显著增加。此外，在多变量分析中，调整后的年龄，性别和并发症，中期因子是心脏events.Conclusion的独立预测因子：血清中期因子水平在HF患者增加，中期因子是一种新的标记物为HF患者的风险分层。（J Cardiac Fail 2010; 16：308 - 313）
Background: Midkine, a heparin-binding growth factor, has various functions such as migration of inflammatory cell and anti-apoptotic effect. Invasion of inflammatory cell and cardiomyocyte apoptosis are involved in development and progression of heart failure (HF). However, the relationship between midkine and HF has not been previously examined. Therefore, we examined clinical significance of serum midkine levels to determine the prognosis of HF patients.Methods and Results: Serum levels of midkine were measured at admission in 216 consecutive patients hospitalized for HF and 60 control subjects. Patients were prospectively followed during a mean follow-up period of 653 375 days with the end points of cardiac death and progressive HF requiring rehospitalization. Serum concentrations of midkine were significantly higher in patients with HF than in controls. Patients with cardiac events had significantly higher concentrations of midkine than those without cardiac events. Kaplan-Meier analysis revealed that cardiac event rates increased markedly as midkine levels rose. Furthermore in the multivariate analysis, after adjustment for age, gender,and complications, midkine was the independent predictor of cardiac events.Conclusion: Serum midkine levels are increased in HF patients, and midkine is a novel marker for risk stratifying HF patients. (J Cardiac Fail 2010;16:308-313)